Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients’ and parents’ quality of life: the phenylketonuria – quality of life (PKU-QOL) questionnaires

Orphanet Journal of Rare Diseases

Annet M Bosch⁴  Khadra Benmedjahed¹  Flavie Moreau-Stucker⁵  Esther Bettiol²  Amy Cunningham⁶  Alberto Burlina³  Antoine Regnault¹ 

[1] Mapi, Health Economics & Outcomes Research and Strategic Market Access, 27 rue de la Villette, Lyon, France;Infection Control Program, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland;Division of Metabolic Diseases, Department of Paediatrics, University Hospital of Padova, Padova, Italy;Department of Pediatrics, Division of Metabolic Disorders, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;EMD Serono Inc, Billerica, Massachusetts, USA;Hayward Genetics Center, Tulane University School of Medicine, New Orleans, Louisiana, USA

关键词: Psychometric validation;    Simultaneous development;    Cross-cultural adaptation;    Parents;    Adolescents;    Children;    Health-related quality of life;    Questionnaires;    Phenylketonuria;    Rare disease;   

Others  :  1209064
DOI  :  10.1186/s13023-015-0261-6

 received in 2014-12-03, accepted in 2015-03-30,  发布年份 2015

【 摘 要 】

Background

The aim of our study was to develop and validate the first set of PKU-specific Health-related Quality of Life (HRQoL) questionnaires that: 1) were developed for patients with PKU and their parents, 2) cover the physical, emotional, and social impacts of PKU and its treatment on patients’ lives, 3) are age specific (Child PKU-QOL, Adolescent PKU-QOL, Adult PKU-QOL), 4) enable the evaluation of the HRQoL of children by their parents (Parent PKU-QOL), and 5) have been cross-culturally adapted for use in seven countries (i.e. France, Germany, Italy, The Netherlands, Spain, Turkey and the UK).

Methods

The PKU-QOL questionnaires were developed according to reference methods including patients’, parents’ and healthcare professionals’ interviews; testing in a pilot study (qualitative step in six countries), and linguistic validation of the finalised pilot versions in Turkish. For finalisation and psychometric validation, the pilot versions were included in a multicentre, prospective, non-interventional, observational study conducted in 34 sites in France, Germany, Italy, The Netherlands, Spain, Turkey and the UK. Iterative multi-trait analyses were conducted. Psychometric properties were assessed (concurrent and clinical validity, internal consistency reliability and test-retest reliability).

Results

Data from 559 subjects (306 patients, 253 parents) were analysed. After finalisation, the PKU-QOL questionnaires included 40 items (Child PKU-QOL), 58 items (Adolescent PKU-QOL), 65 items (Adult PKU-QOL) and 54 items (Parent PKU-QOL), distributed in four modules: PKU symptoms, PKU in general, administration of Phe-free protein supplements and dietary protein restriction. The measurement properties of the Adolescent, Adult and Parent PKU-QOL questionnaires were overall fairly satisfactory, but weaker for the Child questionnaire.

Conclusions

The four PKU-QOL questionnaires developed for different ages (Child PKU-QOL, Adolescent PKU-QOL, Adult PKU-QOL), and for parents of children with PKU (Parent PKU-QOL) are valid and reliable instruments for assessing the multifaceted impact of PKU on patients of different age groups (children, adolescents and adults) and their parents, and are available for use in seven countries. They are very promising tools to explore how patients’ perceptions evolve with age, to increase knowledge of the impact of PKU on patients and parents in different countries, and to help monitor the effect of therapeutic strategies.

【 授权许可】

   
2015 Regnault et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hardelid P, Cortina-Borja M, Munro A, Jones H, Cleary M, Champion MP et al.. The birth prevalence of PKU in populations of European, South Asian and sub-Saharan African ancestry living in South East England. Ann Hum Genet. 2008; 72(Pt 1):65-71.
• [2]Blau N, Van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010; 376(9750):1417-1427.
• [3]Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A et al.. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007; 92(1–2):63-70.
• [4]Poustie VJ, Rutherford P. Dietary interventions for phenylketonuria. Cochrane Database Systematic Reviews. 2000; 2:
• [5]Moyle JJ, Fox AM, Arthur M, Bynevelt M, Burnett JR. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev. 2007; 17(2):91-101.
• [6]Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab. 2010; 99 Suppl 1:S59-S63.
• [7]Gentile JK, Ten Hoedt AE, Bosch AM. Psychosocial aspects of PKU: hidden disabilities–a review. Mol Genet Metab. 2010; 99 Suppl 1:S64-S67.
• [8]MacDonald A, Gokmen-Ozel H, Van Rijn M, Burgard P. The reality of dietary compliance in the management of phenylketonuria. J Inherit Metab Dis. 2010; 33(6):665-670.
• [9]Waisbren SE, Mahon BE, Schnell RR, Levy HL. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. Pediatrics. 1987; 79(3):351-355.
• [10]Belanger-Quintana A, Burlina A, Harding CO, Muntau AC. Up to date knowledge on different treatment strategies for phenylketonuria. Mol Genet Metab. 2011; 104 Suppl:S19-S25.
• [11]Gassio R, Campistol J, Vilaseca MA, Lambruschini N, Cambra FJ, Fuste E. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet? Acta Paediatr. 2003; 92(12):1474-1478.
• [12]Van Spronsen FJ, Belanger-Quintana A. Outcomes of phenylketonuria with relevance to follow-up. JIMD reports. 2011; 1:49-55.
• [13]Bilginsoy C, Waitzman N, Leonard CO, Ernst SL. Living with phenylketonuria: perspectives of patients and their families. J Inherit Metab Dis. 2005; 28(5):639-649.
• [14]Mutze U, Roth A, Weigel JF, Beblo S, Baerwald CG, Buhrdel P et al.. Transition of young adults with phenylketonuria from pediatric to adult care. J Inherit Metab Dis. 2011; 34(3):701-709.
• [15]Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A et al.. How practical are recommendations for dietary control in phenylketonuria? Lancet. 2002; 360(9326):55-57.
• [16]Van Spronsen FJ, Burgard P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis. 2008; 31(6):673-679.
• [17]European Medicines Agency. Reflection paper on the regulatory guidance for the use of healthrelated quality of life (HRQL) measures in the evaluation of medicinal products - EMEA/CHMP/EWP/139391/2004. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf. Accessed Accessed 23 October 2014.
• [18]Bik-Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W et al.. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis. 2008; 31 Suppl 2:S415-S418.
• [19]Bosch AM, Tybout W, Van Spronsen FJ, De Valk HW, Wijburg FA, Grootenhuis MA. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis. 2007; 30(1):29-34.
• [20]Cotugno G, Nicolo R, Cappelletti S, Goffredo BM, Dionisi Vici C, Di Ciommo V. Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr. 2011; 100(8):1144-1149.
• [21]Douglas TD, Ramakrishnan U, Kable JA, Singh RH. Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride. Health Qual Life Outcomes. 2013; 11:218.
• [22]Fidika A, Salewski C, Goldbeck L. Quality of life among parents of children with phenylketonuria (PKU). Health Qual Life Outcomes. 2013; 11:54.
• [23]Landolt MA, Nuoffer JM, Steinmann B, Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr. 2002; 140(5):516-521.
• [24]Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J et al.. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008; 6:25.
• [25]Ten Hoedt AE, Maurice-Stam H, Boelen CC, Rubio-Gozalbo ME, Van Spronsen FJ, Wijburg FA et al.. Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life. J Inherit Metab Dis. 2011; 34(2):391-398.
• [26]Thimm E, Schmidt LE, Heldt K, Spiekerkoetter U. Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents. J Inherit Metab Dis. 2013; 36(5):767-772.
• [27]Ziesch B, Weigel J, Thiele A, Mutze U, Rohde C, Ceglarek U et al.. Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life. J Inherit Metab Dis. 2012; 35(6):983-992.
• [28]Demirdas S, Maurice-Stam H, Boelen CC, Hofstede FC, Janssen MC, Langendonk JG et al.. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. Mol Genet Metab. 2013; 110 Suppl:S49-S56.
• [29]Briançon S, Gergonne B, Guillemein F, Empereur F, Klein S. Disease-Specific Versus Generic Measurement of Health-Related Quality of Life in Cross-Sectional and Longitudinal Studies: an Inpatient Investigation of the SF-36 and Four Disease-Specific Instruments. In: Statistical Methods for Quality of Life Studies. Mesbah M, Cole BF, Ting Lee ML, editors. Kluwer Academic Publisher, Boston; 2002: p.87-99.
• [30]Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ. 1998; 316(7132):690-693.
• [31]Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989; 27(3 Suppl):S217-S232.
• [32]Acquadro C, Conway K, Giroudet C, Mear I. Linguistic Validation Manual for Health Outcome Assessments. Mapi Institute, Lyon; 2012.
• [33]Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A et al.. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005; 8(2):94-104.
• [34]Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K et al.. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet Journal of Rare Disease. 2014.
• [35]Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999; 37(2):126-139.
• [36]Ware JE, Snow KK, Kosinski M, Gandek B. SF-36® Health Survey Manual and Interpretation Guide. New England Medical Center, The Health Institute, Boston; 1993.
• [37]Landgraf JM, Abetz L, Ware JE. The CHQ User’s Manual. New England Medical Center, The Health Institute, Boston; 1996.
• [38]Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959; 56(2):81-105.
• [39]Hays RD, Hayashi T. Beyond internal consistency reliability: rationale and user’s guide for Multitrait analysis program on the microcomputer. Behav Res Methods Instrum Comput. 1990; 22(2):167-175.
• [40]Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951; 16(2):167-188.
• [41]Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991; 12(4 Suppl):142S-158S.
• [42]Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. McGraw-Hill Inc, New York; 1994.
• [43]De Civita M, Regier D, Alamgir AH, Anis AH, Fitzgerald MJ, Marra CA. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics. 2005; 23(7):659-685.